Relypsa
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Relypsa sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Relypsa: 5 sponsored US clinical trials, none currently recruiting.
Relypsa sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hyperkalemia (HK), with 1 trials.
Upper-quartile sponsor footprint
Relypsa sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
NCT03071263
Patiromer With or Without Food for the Treatment of Hyperkalemia
NCT02694744
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
NCT01810939
Evaluation of Patiromer in Heart Failure Patients
NCT00868439
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis
NCT02033317
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Therapeutic Areas
How the Relypsa archive is shaped
5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Hyperkalemia (HK) (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Relypsa: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Relypsa sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Relypsa page
5 registered trials is a research-attention snapshot, not an endorsement of Relypsa or any single study.
- None of Relypsa's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hyperkalemia (HK) is the condition Relypsa studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hyperkalemia (HK) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Relypsa pipeline card: 5 registered trials from official public datasets.Report a data error.